In a reversal of a previous guidance, the UK’s National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending ibrutinib (or routine National Health Service (NHS) use to treat mantle cell lymphoma (MCL) in people who have had only one prior line of therapy.
US healthcare giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen’s Imbruvica (ibrutinib) is currently available to patients in the Cancer Drugs Fund (CDF). It is used to treat patients if their cancer has come back or not responded to first-line treatment. It is considered a life-extending treatment at the end-of-life.
Back in September the cost-effectiveness watchdog rejected the drug for the treatment of mantle cell lymphoma on the NHS.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze